Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited is an Australia-based dermatology company.
The business
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Botanix Pharmaceuticals Secures A$45 Million Capital Raise to Fund API Purchases and Supply Chain Diversification
Botanix secures A$45m to buy APIs and diversify supply; new shares A$0.06 at 45.5% discount; Sofdra posts Q2 FY26 A$9.1m revenue, 24% QoQ rise.
Trump’s CBD Comments Ignite US Cannabis Stocks Surge – Will ASX Companies Follow Suit?
Shares of cannabis and CBD-related companies surged on Monday after US President Donald Trump posted on Truth Social that hemp-derived cannabidiol (CBD), especially in senior healthcare, “could revolutionize” treatment by reducing disease progression and providing an alternative to prescription drugs. He further reiterated his administration is exploring reclassifying marijuana under federal law, a change that could […]
Botanix Pharmaceuticals prepares new drug application for novel gel to treat excessive underarm sweating
Clinical dermatology company Botanix Pharmaceuticals (ASX: BOT) is preparing to submit a new drug application (NDA) for novel asset Sofpironium Bromide gel 15% for the treatment of excessive underarm sweating. The application will go to the US Food and Drug Administration before the end of the September quarter and will be followed up with preparations […]
Botanix Pharmaceuticals tracks commercial dermatology path
Botanix Pharmaceuticals (ASX: BOT) has provided the market with an update on its progress in transforming into a commercial-stage dermatology company following the acquisition of its latest asset, Sofpironium Bromide. The dermatology company had been focused on developing synthetic cannabinoid treatments for skin diseases including rosacea and acne before it announced the acquisition earlier this […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.